HIV i-Base: Looking back through 2024 and forward to 2025…

HIV i-Base released a review of 2024. The key themes in the review of the past year highlight the importance of responding to political changes as much as tracking incredible advances in HIV science. These issues will continue into 2025.

• The impact of political change on HIV care included LGBT+ hate laws in Uganda and extended to questioning the stability of PEPFAR after the US elections.
• Continued investment in new drugs in the exciting ART pipeline were reported at CROI, IAS, R4P and Glasgow — shifting to multiple long-acting combinations.
• Remarkable research into oral PrEP led to exciting changes that includes easier dosing options for everyone.
• Lenacapavir PrEP gets a special category for generating astonishing results — but who will get access and when depends on civil society generating global demand.
• The promise of GLP-1 agonists such as semaglutide have potential in HIV and perhaps addiction management, and possible new indications are suggested every month — but people with HIV have been excluded from research studies.
• Mpox continued throughout 2024 in key endemic countries, largely ignored until WHO recognised the implications of clade 1b in the Democratic Republic of Congo. We reported research throughout the year though including the disappointing results in December from tecovirimat studies.
• Guidelines for HIV treatment and prevention were produced in the UK, Europe and US by some of our most experienced and committed doctors and researchers —and we refresh a list of 14 we covered during the year — which did you miss?
• A few special reports and reviews include the chance to recognise the work of a few friends and colleagues.
• Finally, news about i-Base changes during the year, archives at Bishopsgate Institute and the Wellcome Collection and your chance to help in 2025.

Access the full review here.